Shares of the Australia-based drug developer Mesoblast (ASX:MESO) saw a decline of 66.4% to $1.34 in premarket trading following the US Food and Drug Administration’s (FDA) denial of the firm’s main proposal of cell therapy - remestemcel-L.

This investigational therapy was aimed at treating children under 12 years of age who faced complications post stem cell or bone marrow transplants.

Mesoblast was looking for approval for this experimental therapy over two years since the FDA rejected it the first time.

Mesoblast noted that the FDA demanded further data to back marketing approval.

As of the last close, Mesoblast’s U.S.

listed shares had risen by 37.11% this year.

Mesoblast is a biopharmaceutical company that specializes in developing innovative cellular medicines.

Advanced Health Intelligence (ASX:AHI) shares rise by as much 54.3% to A$0.270, their highest level since June 13.

The healthcare solutions provider has entered into an exclusive license agreement with Shanghai-based company, Changlin Network Technology.

Under the agreement, Advanced Health Intelligence (ASX:AHI) will provide its Biometric Health Assessment to Changlin’s customers via their platform.

An upfront payment of $10 million was paid to Advanced Health Intelligence (ASX:AHI) upon the agreement’s execution.

Furthermore, the company will receive a 25% revenue share of gross sales, with payments scheduled on a quarterly basis.

As a result, the stock has seen its biggest intraday percentage gain since June 22.

As of the last close, Advanced Health Intelligence (ASX:AHI) shares are up 178.4% this year.

Advanced Health Intelligence is a healthcare solutions provider that specializes in biometric health assessments.

Galena Mining (ASX:G1A) sees a significant stock increase of as much as 19.1%, marking its biggest intraday percentage gain since September 2022.

The metals miner announced that its Abra lead-silver project in Western Australia reached its first positive monthly cash flows in July.

Galena Mining also reaffirmed its mining and processing plans for the project for the remainder of 2023, estimating the September quarter will generate between 25,000 to 30,000 tonnes of concentrate.

The company forecasts the September quarter production will bring in revenue estimated between A$50 million and A$60 million and positive operating cash flows.

Galena Mining’s stock has reached its highest level since July 25, despite having fallen 66.4% this year up to the last close.

Galena Mining is a company focused on the exploration and development of mineral resources in Australia.

Shares of Treasury Wine (ASX:TWE) surged as much as 3.9% to A$11.92 in its best day since April 11, as long as gains hold.

The surge is primarily due to Jefferies' decision to upgrade the wine company’s stock to ‘buy’ from ‘hold’, with a new price target set at A$13.00.

Additionally, China has lifted its longstanding tariffs on Australian barley, which have been in place for three years.

Treasury Wine reaps nearly A$200 million in earnings before interest and tax from the Chinese market, according to Jefferies.

This move by China could potentially elevate Treasury Wine’s earnings by roughly A$80 million; however, Jefferies warns that it could take time to rebuild the supply.

Jefferies also anticipates a reduction in costs following the planned closure of the company’s commercial Karadoc winery in North-west Victoria.

Despite these positive developments, Jefferies foresees potential challenges in the American market for lower-priced wine.

Treasury Wine’s shares have been on an uptrend, rising for five straight sessions and hitting their highest since May 29.

Ten out of 17 analysts rate the stock ‘buy’ or higher, four as ‘hold’ and three as ‘sell’ or lower, with a median price target of A$13.40, according to Refinitiv data.

As of the last close, the stock had fallen around 13.9% this year.

Treasury Wine is an Australian wine company that produces and distributes various wine brands globally.

Macquarie has raised its price target on Liontown Resources after the company put in a bid to sell its lithium direct shipping ore product.

The new price target risen to A$3.10 from A$3.00, while Macquarie maintains an outperform rating on Liontown.

According to the battery metals explorer, it has agreed to deliver lithium direct shipping ore product ahead of initial concentrate production at its main Kathleen Valley lithium project.

Macquarie’s projections now include 200kt of Direct Shipping Ore shipments, anticipated to generate roughly A$150 million in cash flow.

Liontown shares have witnessed an upswing as much as 1.1% to A$2.770.

Among the nine analysts evaluating the stock, three rate it as buy or higher, six hold it, and their median price target is A$2.65, according to Refinitiv data.

So far this year, Liontown’s stock has more than doubled from its last closure price.

Liontown Resources is a mineral exploration company focusing on the development of its Kathleen Valley Lithium Project.

Shares of Australian Strategic Materials (ASX:ASM) escalated as much as 8.5% to A$1.855 and marked their highest level since February 22, stretching their increase for the fourth consecutive session.

Last Thursday, the company announced that they have inked a five-year agreement to supply neodymium iron boron (NdFeB) alloy to USA Rare Earth LLC.

The company anticipates the commencement of the supply of NdFeB alloy, a vital component in constructing permanent magnets for electric vehicles and wind turbines, to USA Rare Earth in 2024.

Australian Strategic Materials closed up 5.6% on Thursday and has seen the shares surge by about 21% in the current week.

On Friday, approximately 815,000 shares exchanged hands, significantly over the 30-day average volume of 501,000 shares.

According to the latest closure, the stock has ascended by 19.2% YTD.

Australian Strategic Materials is a mining company that involves in the production and supply of various strategic materials.

Shares of the investment firm Magellan Financial (ASX:MFG) experienced a decrease in funds under management (FUM), which led to a drop as much as 2.1% in value, falling to A$9.02, the lowest it has been since July 27.

The Australian firm announced that FUM was A$39.2 bln by the end of July, which was lower compared to A$39.7 bln in June-end.

Notably, this is the sixth straight month where FUM has dropped.

The company also reported net outflows of A$0.4 bln in July.

Despite currently being on track for the third consecutive session of losses, shares of Magellan Financial have still risen 3% this year, compared to a minor 0.6% uptick on the ASX 200 Financials index.

Magellan Financial is an Australian-based investment firm that has been experiencing a decrease in funds under management over the past six months.

Melbana Energy, an oil and gas exploration company experienced a significant surge in shares, spiking as high as 15% to A$0.115.

This marks the largest intraday gain the company has seen since July 21.

Melbana Energy (ASX:MAY) has announced an adjustment to their estimates, now projecting a significantly higher net pay from a well situated in a Cuban oil field.

The company owns a 30% stake and operates Block 9 PSC onshore, a region on the north coast of Cuba within a known hydrocarbon system.

Notably, the company’s stock was among the top performers on the ASX All Ordinaries index.

Year-to-date, Melbana Energy (ASX:MAY) has experienced an uplift of 58.7% as of the last market close.

Melbana Energy is an Australian-based company specializing in oil and gas exploration.

ChemX Materials recently announced the appointment of Peter Lee as its new Chief Executive Officer.

This comes along with news of a funding facility reaching up to A$6M, which will come via convertible notes and received from an existing institutional shareholder.

ChemX Materials is a leading innovator in the chemical industry.

Shares of Australia’s Flight Centre Travel Group (ASX:FLT) extend their losing streak to a fourth consecutive day, seeing a 3.2% decline, bringing the price to A$21.865 per share.

Macquarie has decided to downgrade their rating for the company to ‘neutral’ from ‘outperform’, a decision that’s been attributed to Flight Centre’s recent surge in valuation.

Year-to-date, FLT shares have seen around a 55% increase, with an 18.5% climb since the end of June.

Despite the downgrade, Macquarie has raised their price target for the stock to A$23.00 from the earlier A$21.30, a decision based on last month’s earnings guidance revision made by Flight Centre.

On July 20th, the company updated their expectations for FY23 underlying EBITDA to be between A$295 million and A$305 million, a striking contrast to last year’s A$183.1 million loss.

Macquarie expects Flight Centre’s earnings through to fiscal 2025 to increase and is forecasting a FY23 EBITDA of A$301 million.

According to Refinitive data, of the 16 analysts that cover the stock, eight rate it as ‘buy’ or higher, six suggest to ‘hold’ and two recommend ‘sell’ or lower with a median price target of A$23.00.

Flight Centre Travel Group (ASX:FLT) is a global travel agency with operations in over 23 countries offering corporate, leisure and wholesale travel.